Bioconjugate Chemistry · 2016 · 42 citations · 30 references
MedicineMedicinal ChemistryNuclear MedicineMolecular ImagingMolecular PharmacologyRadionuclide TherapyPositron Emission TomographyRadiopharmaceutical DesignRadiopharmaceutical TherapyRadiotracer DevelopmentTheranostic ApproachesTheranostic ImagingBruton Tyrosine KinaseGlycogen Synthase Kinase 3 SignalingPet RadiopharmaceuticalsRadiochemical SynthesisRadionuclide LabelingRadiotracer Labeling ChemistryRadiotracer SynthesisTranslational Oncology Drug Development
Three new positron emission tomography (PET) radiotracers of interest to our functional neuroimaging and translational oncology programs have been prepared through new developments in [(11)C]CO2 fixation chemistry. [(11)C]QZ (glutaminyl cyclase) was prepared via a tandem trapping of [(11)C]CO2/intramolecular cyclization; [(11)C]tideglusib (glycogen synthase kinase-3) was synthesized through a tandem trapping of [(11)C]CO2 followed by an intermolecular cycloaddition between a [(11)C]isocyanate and an isothiocyanate to form the 1,2,4-thiadiazolidine-3,5-dione core; [(11)C]ibrutinib (Bruton's tyrosine kinase) was synthesized through a HATU peptide coupling of an amino precursor with [(11)C]acrylic acid (generated from [(11)C]CO2 fixation with vinylmagnesium bromide). All radiochemical syntheses are fully automated on commercial radiochemical synthesis modules and provide radiotracers in 1-5% radiochemical yield (noncorrected, based upon [(11)C]CO2). All three radiotracers have advanced to rodent imaging studies and preliminary PET imaging results are also reported.
30
A Phase II Trial of Tideglusib in Alzheimer's Disease
Simon Lovestone, Merçé Boada, Bruno Dubois et al. · Journal of Alzheimer s Disease · 2015 · 515 citations
Medicine, Neurology, Pharmacology +14
A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy
Eduardo Tolosa, Irene Litvan, Günter U. Höglinger et al. · Movement Disorders · 2014 · 318 citations
Medicine, Neurology, Pharmacology +13